TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04300920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine
Description: 600 mg N-acetylcysteine (NAC) oral tablets three times daily for 24 months.
Study: NCT04452370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral etoposide + anlotinib
Description: anlotinib 12mg qd, d1-14，21days/cycle oral etoposide 75mg qd，d1-10，21days/cycle
Study: NCT04300920

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching oral placebo tablet three times daily for 24 months.
Study: NCT03255525

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Deep friction massage P50
Description: Deep friction massage as described by Dr. James Cyriax, applied with the mean pressure (P50)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep friction massage P25
Description: Deep friction massage as described by Dr. James Cyriax, applied with the percentile 25 of the mean pressure (P25)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep friction massage P75
Description: Deep friction massage as described by Dr. James Cyriax, applied with the percentile 75 of the mean pressure (P75)
Study: NCT04302883

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Transesophageal Echocardiography (TEE)
Description: Ultrasound of heart chambers via esophagus

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transesophageal Echocardiography (TEE)
Description: Ultrasound of heart chambers via esophagus

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Flexible Endoscopic Evaluation of Swallowing
Description: Endoscopical swallowing study

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Flexible Endoscopic Evaluation of Swallowing
Description: Endoscopical swallowing study
Study: NCT00002677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tributyrin
Study: NCT02896426

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative Problem Solving
Description: CPS is an approach for understanding and reducing challenging behavior in youth. Under CPS, caregivers are taught to understand and identify the specific neurocognitive skill deficits that underlie their child's challenging behavior. Then the caregivers are taught to interact with the child in a way that solves chronic behavior problems while building the lagging neurocognitive skills to avoid future problems.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Positive Solutions For Families
Description: Positive Solutions for Families groups provide information for families on how to promote children's social and emotional skills, understand their problem behavior, and use positive approaches to help children learn appropriate behavior.
Study: NCT02927808

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interview
Description: Informational leaflet about the risks of high LDL-C and the importance of adherence to lipid-lowering medication in patients with coronary artery disease. Follow-up motivational interviewing at 1 and 6 months after discharge.
Study: NCT03849469

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XmAb®22841
Description: Monoclonal bispecific antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XmAb®22841
Description: Monoclonal bispecific antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (Keytruda®)
Description: FDA-approved humanized monoclonal antibody
Study: NCT03384849

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI examination
Description: The part of the body that is being scanned and the time of the MRI examination are not relevant.
Study: NCT03475407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozurdex intravitreal injection
Description: 1. Ozurdex intravitreal injection and Antreior Chamber(AC) paracentesis at baseline~2. AC paracentesis at 6 wk~3. intravitreal Ozurdex injection and AC paracentesis at 18wk or 24wk
Study: NCT01517789

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Visual evoked potentials monitoring during neurosurgery - Vision monitor MonOpera®
Description: Visual assessment (visual field, visual acuity, pattern visual evoked potential) are realised before and after surgery.~Flash and steady state visual evoked potential are measured during the surgical procedure at different times.
Study: NCT03536429

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACETAZOLAMIDE oral capsule
Description: Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
Study: NCT01984346

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AtriCure EPi-Sense-AF Guided Coagulation System with VisiTrax
Description: Convergent Epicardial Endocardial Ablation Procedure

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endocardial RF Catheter ablation using Open Irrigated-tip RF Abaltion Catheter with unidirectional or bidirectional steering
Description: Endocardial Catheter Ablation Procedure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endocardial RF Catheter ablation using Open Irrigated-tip RF Abaltion Catheter with unidirectional or bidirectional steering
Description: Endocardial Catheter Ablation Procedure
Study: NCT01548885

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CONTOUR® NEXT EZ BGMS
Description: Study staff performed Blood Glucose (BG) testing with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). Performance of CONTOUR® NEXT EZ BGMS was evaluated across the glucose range of the BGMs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FreeStyle Freedom Lite® BGMS
Description: Study staff performed Blood Glucose (BG) testing with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). Performance of FreeStyle Freedom Lite® BGMS was evaluated across the glucose range of the BGMs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACCU-CHEK® Aviva BGMS
Description: Study staff performed Blood Glucose (BG) testing with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). Performance of ACCU-CHEK® Aviva BGMS was evaluated across the glucose range of the BGMs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TRUEtrack® BGMS
Description: Study staff performed Blood Glucose (BG) testing with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). Performance of TRUEtrack® BGMS was evaluated across the glucose range of the BGMs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OneTouch® Ultra®2 BGMS
Description: Study staff performed Blood Glucose (BG) testing with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). Performance of OneTouch® Ultra®2 BGMS was evaluated across the glucose range of the BGMs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
Study: NCT01165333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilengitide dose escalation
Description: Cilengitide will be administered intravenously over 60 minutes, twice a week, at a given dose.~The Cilengitide dose (mg/m²/infusion)levels are as follows :~* 240~* 480~* 720~* 1200~* 1800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilengitide
Description: Patients will be treated at the recommended dose in order to confirm the recommended cilengitide dose and to carry out the exploratory investigations

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Concomitant radiotherapy
Description: 1.8 Gy per fraction for a total of 54 Gy over 6 weeks, from monday to friday of the first cycle. The radiation will imperatively begin between 3 and 7hours after the end of Cilengitide infusion.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Concomitant radiotherapy
Description: 1.8 Gy per fraction for a total of 54 Gy over 6 weeks, from monday to friday of the first cycle. The radiation will imperatively begin between 3 and 7hours after the end of Cilengitide infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic
Description: A pharmacokinetic assessment for Cilengitide will be carried for all patients. The pharmacokinetic (PK) samples will be drawn during day 1 and day 2 of the first cycle of treatment.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic
Description: A pharmacokinetic assessment for Cilengitide will be carried for all patients. The pharmacokinetic (PK) samples will be drawn during day 1 and day 2 of the first cycle of treatment.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic
Description: For every patient 1 blood sample will be taken before study treatment. These blood samples can be made at any hour of the day, and does not require to be taken on an empty stomach. DNA will be extracted in the Laboratory of Pharmacology.Constitutional polymorphisms of genes will be measured before the treatment initiation.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic
Description: For every patient 1 blood sample will be taken before study treatment. These blood samples can be made at any hour of the day, and does not require to be taken on an empty stomach. DNA will be extracted in the Laboratory of Pharmacology.Constitutional polymorphisms of genes will be measured before the treatment initiation.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Exploratory investigation
Description: Evaluate the metabolic impact of the treatment with dynamic MRI (diffusion, perfusion, spectro), and with FDG-PETand sestamibi SPECT.
Study: NCT03621618

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: dobutamine
Description: evaluation of effects of dobutamine on dynamic arterial elastance in cardiac failure

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: norepinephrine
Description: evaluation of effects of norepinephrine on dynamic arterial elastance in sepsis
Study: NCT04494815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SR419
Description: Each participant will receive 1 dose of 20 mg SR419 oral suspension.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: active control
Description: Each participant will receive 1 dose of 300 mg active control capsule.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: active control
Description: Each participant will receive 1 dose of 300 mg active control capsule.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SR419 placebo
Description: Each participant will receive 2 doses of SR419 placebo oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: active control placebo
Description: Each participant will receive 2 doses of active control placebo capsule.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: active control placebo
Description: Each participant will receive 2 doses of active control placebo capsule.
Study: NCT03394170

Intervention type: OTHER
Intervention: Collection of specimens prior to and during surgery
Description: Collection of specimens prior to and during surgery

Intervention type: OTHER
Intervention: Collection of specimens prior to and during surgery
Description: Collection of specimens prior to and during surgery
Study: NCT04485169

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Plasma Exchange
Description: a. 1-1.5 plasma volume exchange, 2/3rd plasma should be replacing with FFP to avoid coagulopathy, adequate dieresis to prevent volume overload, 1-5 sessions in total, 1 session daily
Study: NCT03711838

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo consisted of 248 ml water and 2 ml of natural, non-caloric, flavoring-sweetener containing sucralose.
Study: NCT02425683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: 120 mg or 160 mg by mouth each day for first 21 days of each 28-day cycle, for maximum of 6 cycles
Study: NCT03471468

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: kinetics of microparticles under chemotherapy
Description: Blood samples done before chemotherapy and 6 hours later for each of six chemotherapies required by the protocol.
Study: NCT04007003

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: training in optimal insulin injection technique
Description: the training will be delivered in person as well as through online training modules via the BD and Me(TM) platform
Study: NCT02950545

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo Lenses
Description: AcuVue Oasys Bandage Lenses with no prescription

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo Lenses
Description: AcuVue Oasys Bandage Lenses with no prescription

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo Lenses
Description: AcuVue Oasys Bandage Lenses with no prescription
Study: NCT00122746

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy alone
Description: EBRT pelvis 46 Gy 4 field box technique + ICBT LDR 1x30 Gy/A or HDR 3x8 Gy/A

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy with cisplatin
Description: EBRT pelvis 46 Gy 4 field box technique + ICBT LDR 1x30 Gy/A or HDR 3x8 Gy/A + weekly cisplatin 30 mg/m2 during EBRT
Study: NCT03070977

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interprofessional clinical training unit
Description: In 2015, Psychiatry in Slagelse established an interprofessional clinical training unit. The aim was to create a new environment for learning, where students could learn from each other and develop competence in interprofessional collaboration. In the training unit there are more students than in the other standard psychiatric wards and several professions are included.~A facilitator team is responsible for the interprofessional training. In autumn 2016 seven professionals participate in course of facilitating interprofessional collaboration and training. The intervention involved the total staff participation in an initial workshop.~The training unit is based on two educational interventions: Student participation in clinical care teams and interprofessional group tuition sessions.
Study: NCT02494349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JLP-1207
Description: The subjects will receive JLP-1207 under fed(high fat meal) condition. After washout period, the subjects will receive Solifenacin 5mg and Tamsulosin 0.2mg under fed(high fat meal) condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin 5mg+Tamsulosin 0.2mg
Description: The subjects will receive Solifenacin 5mg and Tamsulosin 0.2mg under fed(high fat meal) condition. After washout period, the subjects will receive JLP-1207 under fed(high fat meal) condition.
Study: NCT02769572

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: real moxibustion
Description: 3 times a week for 4 consecutive weeks,totally 12 sessions at 3 acupoints (ST35, EX-LE4, ST36 )

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo gel
Description: 4 grams per knee, 4 times per day, for 4 weeks
Study: NCT02950545

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo Lenses
Description: AcuVue Oasys Bandage Lenses with no prescription

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo Lenses
Description: AcuVue Oasys Bandage Lenses with no prescription

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo Lenses
Description: AcuVue Oasys Bandage Lenses with no prescription

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spherical Lenses
Description: 1-DAY ACUVUE® MOIST contact lenses

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spherical Lenses
Description: 1-DAY ACUVUE® MOIST contact lenses

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spherical Lenses
Description: 1-DAY ACUVUE® MOIST contact lenses

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spherical Lenses
Description: 1-DAY ACUVUE® MOIST contact lenses

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spherical Lenses
Description: 1-DAY ACUVUE® MOIST contact lenses
Study: NCT02769572

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: diclofenac sodium gel
Description: 4 grams per knee, 4 times per day, for 4 weeks
Study: NCT02950545

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spherical Lenses
Description: 1-DAY ACUVUE® MOIST contact lenses

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toric Lenses
Description: 1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toric Lenses
Description: 1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses
Study: NCT02769572

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sham moxibustion
Description: 3 times a week for 4 consecutive weeks,totally 12 sessions at 3 acupoints (ST35, EX-LE4, ST36 )
Study: NCT01492114

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: Subjects in the group resvetarol first will be submitted to: 30 days of treatment with Transmax (resveratrol, 500 mg, Biotivia Bioceuticals LLC), one tablet/day in the morning at fasting; then to 30 days of wash-out (no supplementation), and then to 30 days of treatment with placebo (one tablet/day in the morning at fasting).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: resveratrol
Description: Subjects in the group Placebo first will be submitted to: 30 days of treatment with placebo, one tablet/day in the morning at fasting; than to 30 days of wash-out (no supplementation), and then to 30 days of treatment with Transmax (resveratrol, 500 mg) (one tablet/day in the morning at fasting).
Study: NCT00781781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: High risk: Total dose 100 mg in 5 doses of 20 mg, days -8 to -4 (inclusive) Low risk: Total dose 50 mg inn 5 dosing OF 10 mg, days -5 to -1 (inclusive).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: High risk: Total dose 100 mg in 5 doses of 20 mg, days -8 to -4 (inclusive) Low risk: Total dose 50 mg inn 5 dosing OF 10 mg, days -5 to -1 (inclusive).
Study: NCT02257021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 BS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 BS
Study: NCT03749993

Intervention type: OTHER
Group type: OTHER
Intervention: Screening
Description: Use of bpMRI for opportunistic prostate cancer screening.
Study: NCT02257021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose of ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose of ritonavir
Study: NCT03785132

Intervention type: PROCEDURE
Intervention: Cardiac surgery
Description: The relationship between performance measurement of blood pressure during cardiac surgery (before, during and after cardiopulmonary bypass) and postoperative mortality
Study: NCT03288779

Intervention type: DEVICE
Group type: OTHER
Intervention: Theta Burst Stimulation
Description: Transcranial magnetic stimulation with theta burst stimulation
Study: NCT03388177

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga-based therapy

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as usual

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Study: NCT04138524

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SAFIR©
Description: Early Supportive intervention for families of patients with acquired brain injuries.
Study: NCT01391312

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: botulinum toxin Type A
Description: botulinum toxin Type A 20U (total dose) injected into the glabellar region on Day 0.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline (placebo)
Description: Normal saline (placebo) injected into the glabellar region on Day 0.
Study: NCT03575091

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-individualized
Description: Comparing two experimental interventions with standard care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized
Description: Comparing two experimental interventions with standard care
Study: NCT02316470

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VLA84
Description: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VLA84
Description: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VLA84
Description: a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: phosphate buffered saline (PBS) solution

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: phosphate buffered saline (PBS) solution